These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2438954)

  • 21. Immunohistological study of malignant diffuse mesotheliomas of the pleura.
    Loosli H; Hurlimann J
    Histopathology; 1984 Sep; 8(5):793-803. PubMed ID: 6083969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
    Oates J; Edwards C
    Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemistry in the diagnosis of malignant mesothelioma.
    Pfaltz M; Odermatt B; Christen B; Rüttner JR
    Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
    Ordóñez NG
    Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
    Tot T
    Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma.
    Attanoos RL; Goddard H; Gibbs AR
    Histopathology; 1996 Sep; 29(3):209-15. PubMed ID: 8884348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas.
    Khoury N; Raju U; Crissman JD; Zarbo RJ; Greenawald KA
    Hum Pathol; 1990 Aug; 21(8):811-9. PubMed ID: 1696923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical staining in malignant mesotheliomas.
    Strickler JG; Herndier BG; Rouse RV
    Am J Clin Pathol; 1987 Nov; 88(5):610-4. PubMed ID: 2445194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
    Kawai T; Greenberg SD; Truong LD; Mattioli CA; Klima M; Titus JL
    Am J Pathol; 1988 Feb; 130(2):401-10. PubMed ID: 2449084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of anticarcinoembryonic antigen, human milk factor globulin, and antikeratin antibodies in differentiating mesothelioma from lung carcinoma.
    Joglekar VM; Oliver D; Harris M
    Br J Ind Med; 1991 Jan; 48(1):34-7. PubMed ID: 1704251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carcinoembryonic antigen-like reactivity in malignant mesothelioma. A comparison between different commercially available antibodies.
    Dejmek A; Hjerpe A
    Cancer; 1994 Jan; 73(2):464-9. PubMed ID: 8293414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma.
    Attanoos RL; Webb R; Gibbs AR
    Histopathology; 1997 Mar; 30(3):260-3. PubMed ID: 9088956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
    Dejmek A; Hjerpe A
    Cytopathology; 2000 Feb; 11(1):8-17. PubMed ID: 10714371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis.
    Skov BG; Lauritzen AF; Hirsch F; Nielsen HW
    Histopathology; 1994 Jun; 24(6):553-7. PubMed ID: 8063283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin.
    Duggan MA; Masters CB; Alexander F
    Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
    Ordóñez NG
    Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies.
    Noguchi M; Nakajima T; Hirohashi S; Akiba T; Shimosato Y
    Hum Pathol; 1989 Jan; 20(1):53-7. PubMed ID: 2912874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Ylagan LR; Zhai J
    Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.